Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - INNOVUS PHARMACEUTICALS, INC. | innv8k_aug102018.htm |
|
Exhibit 99.1
Innovus Pharma Signs Purchase Agreement with “Showcase
– The Home of the Hottest Trends” to Sell the
Company’s Apeaz® Cream for the Relief of Arthritis Pain
in its 110 “Showcase” Retail Stores in the United
States and Canada
Apeaz® is the Fifth Company Product to Be Sold in Retails
Stores in
the U.S. and Canada
San
Diego, CA, August 10, 2018 – Innovus Pharmaceuticals, Inc.
("Innovus Pharma" or the “Company”) (OTCQB Venture
Market: INNV), an emerging commercial-stage pharmaceutical company
that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men’s and
women's health and respiratory diseases, today announced that it
has entered into a purchase agreement with the nationwide retail
store chain Showcase, a Canadian company for its drug Apeaz®,
for arthritis pain relief. Apeaz® will be available in
Showcase’s 110 stores across the United States and Canada and
on its www.ShopAtShowcase.com portal, starting mid-August,
2018.
“We
are very pleased to have entered into this purchase agreement with
Showcase for our Apeaz® product as we continue the expansion
of our products into select retail stores,” said Dr. Bassam
Damaj, the President and Chief Executive Officer of Innovus Pharma.
“Apeaz® is the fifth Innovus Pharma product to hit the
shelves of retail stores in the U.S. or Canada in addition to
Zestra®, Zestra Glide®, Uxor® (EjectDelay®) and
Androferti®.”
The
Company’s Apeaz® drug continues to be in demand in both
the United States and Canadian markets with 10,218 units shipped in
2018 through June 30 in the United States and 10,875 units shipped
in Canada since its launch in that country in mid-April
2018.
About Apeaz®
Apeaz®
is an FDA OTC monograph compliant drug for arthritis pain relief.
The product was approved by Health Canada in January 2018 as a
Natural Health Product (“NHP”) for sales in that
country for the same indication.
According
to Markets & Markets
(October 2016 Report Code: MD 4660), the market for the arthritis
and other related joint pain is estimated to be at approximately
$850 million in 2016 and projected to grow at a CAGR of 5.0% during
2017 to 2021. For more information on Apeaz®, please visit our
website at www.apeaz.com.
To the Company’s knowledge, Apeaz® is the
only Canadian NHP product published and commercialized to reduce
all signs and symptoms of arthritis in the collagen induced mouse
model. In addition, our proprietary deep penetration formulation
was shown to penetrate the joint tissues where the inflammation and
joint damage take place (J Immunol April 1, 2009, 182 (1
Supplement) 50.20).
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging
OTC consumer goods and specialty pharmaceutical company engaged in
the commercialization, licensing and development of safe and
effective non-prescription medicine and consumer care products to
improve men’s and women’s health and vitality and
respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health
solutions through its (a) OTC medicines and consumer and health
products, which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists and
therapists, and (c) directly to consumers through our on-line
channels, retailers and wholesalers. The Company is dedicated to
being a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products. The
Company is actively pursuing opportunities where existing
prescription drugs have recently, or are expected to, change from
prescription (or Rx) to OTC.
For
more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com;
and www.diabasens.com.
|
|
|
About Showcase
Showcase is the Home of the Hottest Trends, and the world's largest
retailer of its kind. With 100+ permanent stores in Canada's best
shopping centers and the United States, Showcase offers the most
fun, interactive, new, and unique products ever - all in a retail
environment where you can "try it before you buy it." They call it
retail-tainment! Founded in 1994 in Edmonton AB, Showcase now is
coast-to-coast in every major market across Canada.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements
under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company,
including, but not limited to, projected revenues from the
Apeaz® product and other products, estimated market for its
products, and statements about achieving its other development,
growth, commercialization, financial and staffing objectives.
Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company's most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed
on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC's website or without charge from
the Company.
###
Contact:
Randy
Berholtz
Innovus
Pharma Investor Relations
Tel: +1
858 249 7865
ir@innovuspharma.com